...
首页> 外文期刊>Japanese Journal of Pharmacology >Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters.
【24h】

Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters.

机译:通过同时监测血液动力学和电生理参数,评估了III类抗心律不齐药物多非利特对原位犬心脏的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The cardiovascular profile of dofetilide was examined using halothane-anesthetized, closed-chest in vivo canine model (n=6). Dofetilide was administered at the dose of 1, 10 or 100 microg/kg, i.v. over 10 min with a pause of 20 min. After the lowest infusion rate, no significant change was detected in any of the cardiovascular parameters. Infusion of 10 microg/kg dofetilide, which was close to the submaximal clinically effective antiarrhythmic dose, decreased the heart rate and prolonged the ventricular repolarization phase and refractory period. After the highest dose of dofetilide, the cardiac output and left ventricular contraction decreased during sinus rhythm, the latter of which was not changed during the constant heart rate of 150 beats/min, while the dose-related effects were observed on the heart rate, repolarization phase and refractory period. The afterload and preload to the left ventricle and AV nodal as well as intraventricular conductions were hardly affected even at 100 microg/kg, i.v. These results obtained in the in vivo canine model support the previous reports describing that dofetilide possesses a highly selective blocking property for I(Kr). Moreover, the absence of effects on the afterload and preload to the left ventricle and the cardiac conduction makes dofetilide favorable as an antiarrhythmic drug because it is often used for patients with moderate to severe left ventricular dysfunction.
机译:使用氟烷麻醉的封闭胸腔体内犬模型检查了多非利特的心血管特征(n = 6)。多芬利特以1、10或100微克/千克的剂量静脉内给药。超过10分钟,停顿20分钟。最低输注速度后,未发现任何心血管参数发生明显变化。输注接近临床有效抗心律失常剂量以下的最大剂量的10微克/千克多非利特,可降低心率并延长心室复极化期和不应期。给予最大剂量的多芬利特后,窦性心律期间心输出量和左心室收缩下降,在恒定心率150次/分钟下后者没有变化,而剂量相关的影响对心律有影响,再极化阶段和不应期。左心室和AV结的后负荷和预负荷以及心室内传导即使在100微克/千克静脉内也几乎不受影响。在体内犬模型中获得的这些结果支持了先前的报道,该报道描述了多芬利特具有对I(Kr)的高度选择性阻断特性。此外,对左心室的后负荷和前负荷以及心脏传导的影响没有影响,使得多非利特作为抗心律失常药是有利的,因为它经常用于中度至重度左心功能不全的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号